Medivation's (MDVN) Talazoparib Acquisition is 'Good Use of Cash' - Maxim (BMRN)
Get Alerts MDVN Hot Sheet
Rating Summary:
12 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 13 | New: 16
Join SI Premium – FREE
Maxim affirms its Buy rating and $17 price target on Medivation (Nasdaq: MDVN) following news that the company and BioMarin Pharmaceutical entered into an asset purchase agreement under which Medivation will acquire all worldwide rights to talazoparib (formerly referred to as BMN 673), a highly-potent, orally-available poly ADP ribose polymerase (PARP) inhibitor currently in a Phase 3 study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.
Analyst Jason Kolbert offered the following commentary:
- Medivation and BioMarin (Nasdaq: BMRN) have announced an asset purchase agreement in which Medivation will acquire all rights to talazoparib (a potent, orally-available poly ADP ribose polymerase PARP) inhibitor (it has shown activity against cancers involving defects in DNA repair). It is currently in a Phase III study for the treatment of patients with deleterious germline BRCA 1 or BRCA 2 mutations and locally advanced and/or metastatic breast cancer.
- We applaud the acquisition and believe it is a good use of cash ($410M upfront and $160M in milestones plus royalties) for a late-stage asset in a therapeutic area (breast cancer) in which we believe Medivation can surprise with Xtandi (triple-negative BC).
- Medivation supplied analysts with selected publications, which we are reviewing. Suffice to say, the science in this area is fascinating, well-researched, and cutting-edge. Please ask if you would like a copy of the paper(s).
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 23andMe (ME) CEO Wojcicki considering taking company private - 13D
- SL Green Realty (SLG) Completes $2.1 Billion of Debt Refinancings
- UBS Downgrades Applus Services SA (APPS:SM) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!